These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31229471)

  • 1. Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease.
    Schindlbeck KA; Eidelberg D
    Lancet Neurol; 2019 Aug; 18(8):713-714. PubMed ID: 31229471
    [No Abstract]   [Full Text] [Related]  

  • 2. Exploring Braak's Hypothesis of Parkinson's Disease.
    Rietdijk CD; Perez-Pardo P; Garssen J; van Wezel RJ; Kraneveld AD
    Front Neurol; 2017; 8():37. PubMed ID: 28243222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?
    Halliday G; McCann H; Shepherd C
    Expert Rev Neurother; 2012 Jun; 12(6):673-86. PubMed ID: 22650170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Staging of alpha-synuclein in the olfactory bulb in a model of Parkinson's disease: cell types involved.
    Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Mohedano-Moriano A; Fradejas N; Calvo S; Argandoña-Palacios L; Garcia-Muñozguren S; Martinez-Marcos A
    Mov Disord; 2010 Aug; 25(11):1701-7. PubMed ID: 20574962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining Braak's hypothesis by imaging Parkinson's disease.
    Brooks DJ
    Mov Disord; 2010; 25 Suppl 1():S83-8. PubMed ID: 20187242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
    Miraglia F; Betti L; Palego L; Giannaccini G
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut?
    Kujawska M; Jodynis-Liebert J
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Parkinson's disease start in the gut?
    Lionnet A; Leclair-Visonneau L; Neunlist M; Murayama S; Takao M; Adler CH; Derkinderen P; Beach TG
    Acta Neuropathol; 2018 Jan; 135(1):1-12. PubMed ID: 29039141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease.
    Woulfe JM; Gray MT; Gray DA; Munoz DG; Middeldorp JM
    Parkinsonism Relat Disord; 2014 Jul; 20(7):685-94. PubMed ID: 24726430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease.
    Kohl Z; Ben Abdallah N; Vogelgsang J; Tischer L; Deusser J; Amato D; Anderson S; Müller CP; Riess O; Masliah E; Nuber S; Winkler J
    Neurobiol Dis; 2016 Jan; 85():206-217. PubMed ID: 26523794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cortical Pathogenic Theory of Parkinson's Disease.
    Foffani G; Obeso JA
    Neuron; 2018 Sep; 99(6):1116-1128. PubMed ID: 30236282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Braak's hypothesis and non-motor symptoms of Parkinson disease].
    Saito Y; Murayama S
    Brain Nerve; 2012 Apr; 64(4):444-52. PubMed ID: 22481517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Threshold Theory for Parkinson's Disease.
    Engelender S; Isacson O
    Trends Neurosci; 2017 Jan; 40(1):4-14. PubMed ID: 27894611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathophysiological process underlying Parkinson's disease: motor & non-motor symptoms].
    Takeda A; Baba T; Kikuchi A; Sugeno N; Hasegawa T; Itoyama Y; Ishioka T; Hirayama K; Mori E
    Rinsho Shinkeigaku; 2009 Nov; 49(11):888-9. PubMed ID: 20030239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sleep behavior disorder (RBD) in synucleionopaties].
    Glas Srp Akad Nauka Med; 2009; (50):7-15. PubMed ID: 20666111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve.
    Uemura N; Yagi H; Uemura MT; Hatanaka Y; Yamakado H; Takahashi R
    Mol Neurodegener; 2018 May; 13(1):21. PubMed ID: 29751824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lewy body-related alpha-synucleinopathy in the aged human brain.
    Jellinger KA
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1219-35. PubMed ID: 15480835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.